December 6, 2022

Medical Trend

Medical News and Medical Resources

CAR-T is still the mainstream in Global cancer cell immunotherapy projects

CAR-T is still the mainstream in Global cancer cell immunotherapy projects.

 

 

CAR-T is still the mainstream in Global cancer cell immunotherapy projects.  Nature’s sub-publication: Overview of global cancer cell immunotherapy clinical projects, more than 2000 pipelines, CAR-T is still the mainstream.

Cellular immunotherapy for cancer is a therapy in which normal or bioengineered human cells are transplanted or transferred into the body of cancer patients to achieve the effect of cancer treatment.

As early as 2013, some scientists predicted that the therapy would develop into the “third pillar of future medicine” and be widely used in disease treatment. In recent years, the movement of capital and biopharmaceutical companies is undoubtedly making the era of cancer cell therapy more and more important. Coming closer.

Recently, IQVIA, a world-renowned consulting company in the medical industry, and the Cancer Research Institute (CRI), a non-profit organization, published an analyst report entitled “The clinical pipeline for cancer cell therapies” in Nature Reviews Drug Discovery, a subsidiary of Nature. , Describes the current global clinical research and development picture of cancer cell immunotherapy.

 

 

CAR-T therapy is still the mainstream, and the application of allogeneic cells is growing rapidly

The main types of cellular immunotherapy include CAR-T, TCR-transduced T cells (TCR-T), tumor infiltrating lymphocytes (TIL) and natural killer (NK) cells, etc. Among them, CAR-T therapy is a hot field in the clinic. The current five cell therapies approved by the U.S. Food and Drug Administration (FDA) are all from this field. From the perspective of development prospects, the CAR-T field is also bright. Frost & Sullivan pointed out that by 2030, the global CAR-T market is expected to reach 21.8 billion US dollars, with a compound annual growth rate of 22.1 from 2024 to 2030. %.

From this report, the global cell therapy pipeline is steadily advancing. As of April 16, 2021, there are 2,073 active cell therapy drugs under development worldwide, 572 more than the data released in 2020, an increase The rate is 38%. In the project that can identify the source of cells, 835 pipelines use patient’s autologous cells, twice the number of allogeneic cells. However, in the past year, the application of allogeneic cells has increased significantly, and preclinical and clinical phase 1 projects have increased by more than 40% year-on-year.

Among more than 2,000 cell therapies, CAR-T is still the mainstream, with 299 new clinical pipelines, an increase of 35% over 2020, and most (80%) pipelines are in preclinical or clinical phase 1. In terms of other cell therapies, 80 new drugs under development in the TCR field, 67 new pipelines in the NK/NKT field, and 51 new pipelines for new T cells. Some of these projects have entered Phase 2 or Phase 3 clinical trials. .

 


CD19, BCMA, etc. are still popular targets for hematoma, while solid tumor targets remain basically unchanged

In the field of hematoma, what is the hottest target in cellular immunotherapy?

Judging from the five products approved by the FDA, CD19 with four listed drugs and BCMA with one listed product are undoubtedly one of the hottest tracks. After these two targets, CD22, CD20 and other fields have also ushered in more and more settlers. However, judging from the growth trend, the growth of these targets in the past year is much lower than the statistics last year. According to the report, this may be due to the saturation of the market and the impact of COVID-19 on drug development.

From the perspective of solid tumors, the targets under research remain basically unchanged, and the number of undisclosed tumor-associated antigens (TAA) still tops the list. It is worth noting that therapies targeting Glypican 2 and 3 (GPC2/3) will double every year between 2019 and 2021, and will be concentrated in the field of liver cancer.

 

 

China and the United States are leading the world in research projects, solid tumors are still difficult to treat

According to the report, according to the data of ClinicalTrials.gov, thanks to the development of CAR-T cell therapy clinical projects, as of April 2021, there are a total of 1,358 active cell therapy trials worldwide, an increase of 43% compared with the same period last year, and the growth rate is 2019 2 times the data for the period from 2016 to 2020. Most of the trials are still focused on the field of hematoma, and 40% of the projects targeting solid tumors are in the early stages. It can be seen that solid tumors are still a difficult point in cellular immunotherapy.

At present, the United States is still the leader in cellular immunotherapy, with 791 cell therapy projects in progress, while China’s domestic enthusiasm for cellular immunotherapy is not inferior, with the number of projects reaching 695. The growth of the two is respectively compared with the same period last year An increase of 31% and 40%. From the perspective of project sponsors, the distribution in China is more balanced, with 40% coming from academic institutions, 60% coming from pharmaceutical manufacturers, and 80% of the projects in the United States are supported by pharmaceutical manufacturers.

Cancer is currently one of the hottest tracks for venture capital in the medical and health field, and cellular immunotherapy is considered one of the most promising innovative therapies to overcome tumors. Since 2017, the world’s first batch of CAR-T therapies has been approved, and the cellular immunotherapy industry has ushered in unprecedented development opportunities. This report further reveals the worldwide enthusiasm for cellular immunotherapy. As some cell therapies enter a critical clinical stage, it is believed that in the near future, the cell therapy market will enter an era of competition, and cancer patients will also usher in more treatment options.

 

 

 

 

(source:internet, reference only)


Disclaimer of medicaltrend.org